Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K, Akagi T, Shimosegawa K, Sugawara T, Ishizawa K, Ito S, Murai K, Motegi M, Yokoyama H, Noji H, Tajima K, Kimura J, Chou T, Ogawa K, Harigae H, Kubo K, Oba K, Sakamoto J, Ishida Y. Murai K, et al. Among authors: motegi m. Eur J Haematol. 2015 Dec;95(6):558-65. doi: 10.1111/ejh.12536. Epub 2015 Mar 25. Eur J Haematol. 2015. PMID: 25703064 Clinical Trial.
Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.
Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, Kondo T, Motegi M, Kato Y, Mita M, Saito H, Yoshida C, Torimoto Y, Kimura T, Wano Y, Nomura J, Yamamoto S, Mayama K, Honma R, Sugawara T, Sato S, Shinagawa A, Abumiya M, Niioka T, Harigae H, Sawada K. Takahashi N, et al. Among authors: motegi m. Biomark Res. 2014 Mar 20;2(1):6. doi: 10.1186/2050-7771-2-6. Biomark Res. 2014. PMID: 24650752 Free PMC article.
Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, Noguchi M, Kimura H, Handa H, Mitani K, Miura M, Wakita H, Takahashi N; STAT study group. Noguchi S, et al. Int J Hematol. 2018 Aug;108(2):176-183. doi: 10.1007/s12185-018-2459-6. Epub 2018 Apr 30. Int J Hematol. 2018. PMID: 29713954 Clinical Trial.
Treatment of multiple myeloma in Akita: features and outcomes in the era of novel agents.
Shida S, Takahashi N, Niioka T, Kitabayashi A, Kawabata Y, Kume M, Saitoh H, Hatano Y, Ichikawa Y, Kuroki J, Motegi M, Kobayashi T, Kameoka Y, Tagawa H, Fujishima N, Yoshioka T, Hirokawa M, Miura M, Sawada K. Shida S, et al. Among authors: motegi m. J Clin Exp Hematop. 2014;54(1):89-93. doi: 10.3960/jslrt.54.89. J Clin Exp Hematop. 2014. PMID: 24942951 Free article. No abstract available.
148 results